Received Apr 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Administration of second pediatric dose; Administration of second pediatric dose; Second dose early; Administration of first pediatric dose; Administration of first pediatric dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 42-year-old female patient who received HBV (Engerix B pediatric) for prophylaxis. Co-suspect products included HBV (Engerix B pediatric) (batch number LG749, expiry date 13-SEP-2026) for prophylaxis. On 17-MAR-2026, the patient received the 2nd dose of Engerix B pediatric. On 13-MAR-2026, the patient received the 1st dose of Engerix B pediatric. On 13-MAR-2026, not applicable after receiving Engerix B pediatric, 14 days after receiving Engerix B pediatric and 18 days after starting Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: Administration of first pediatric dose) and underdose (Verbatim: Administration of first pediatric dose). On 17-MAR-2026, the patient experienced adult use of a child product (Verbatim: Administration of second pediatric dose), underdose (Verbatim: Administration of second pediatric dose) and drug dose administration interval too short (Verbatim: Second dose early). The outcome of the adult use of a child product, underdose, drug dose administration interval too short, adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 14-APR-2026 The reporter reported about the administration after a 42-year-old patient received 2 pediatric doses on 13-MAR-2026 and 17-MAR-2026. The batch number was not provided upon follow- up with the reporter.